Can cutaneous telangiectasiae as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer?

[1]  L. Holmberg,et al.  Radiation to supraclavicular and internal mammary lymph nodes in breast cancer increases the risk of stroke , 2009, British Journal of Cancer.

[2]  S. Tyldesley,et al.  Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  G. Giotopoulos,et al.  Refining the evidence for GSTA1 and eNOS genetic effects on risk of radiotherapy‐induced telangiectasia , 2008, International journal of cancer.

[4]  S. Darby,et al.  Cardiac dose from tangential breast cancer radiotherapy in the year 2006. , 2008, International journal of radiation oncology, biology, physics.

[5]  Esther J. Kuiper,et al.  The Angio-Fibrotic Switch of VEGF and CTGF in Proliferative Diabetic Retinopathy , 2008, PloS one.

[6]  M. Namer,et al.  Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  J R Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.

[8]  J. Forbes,et al.  Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Tyldesley,et al.  Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. , 2007, International journal of radiation oncology, biology, physics.

[10]  G. Steel.  Radiobiology of Normal Tissues , 2007 .

[11]  W. Mackillop,et al.  A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  M. Plumb,et al.  The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes , 2007, British Journal of Cancer.

[13]  Wei-Ting Hwang,et al.  Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[15]  F. V. van Leeuwen,et al.  Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Yarnold,et al.  TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  J. Bonneterre,et al.  Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Charles Mw,et al.  Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. , 2003 .

[19]  Wilfred Levin,et al.  Late radiation-related fibrosis: pathogenesis, manifestations, and current management. , 2003, Seminars in radiation oncology.

[20]  Lawrence B Marks,et al.  Normal tissue effects: reporting and analysis. , 2003, Seminars in radiation oncology.

[21]  J. Nortier,et al.  Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients. a prospective, comparative, non-randomised study. , 2003, European journal of cancer.

[22]  P. Hall,et al.  Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women , 2003, BMJ : British Medical Journal.

[23]  A. Hajeer,et al.  Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients , 2003, International journal of radiation biology.

[24]  S. Underwood,et al.  Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  I. Lax,et al.  Partial irradiation of the heart. , 2001, Seminars in radiation oncology.

[26]  J. G. Li,et al.  Breast-conserving radiation therapy using combined electron and intensity-modulated radiotherapy technique. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  W. Mackillop,et al.  Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. , 1999, International journal of radiation oncology, biology, physics.

[28]  L. Rutqvist,et al.  Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  W. Mackillop,et al.  Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Requena,et al.  Cutaneous vascular anomalies. Part I. Hamartomas, malformations, and dilation of preexisting vessels. , 1997, Journal of the American Academy of Dermatology.

[31]  I. Lax,et al.  Evaluation of irradiated heart volumes in stage I breast cancer patients treated with postoperative adjuvant radiotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Jacques Bernier,et al.  Late effects toxicity scoring: the SOMA scale , 1995 .

[33]  J O Archambeau,et al.  Pathophysiology of irradiated skin and breast. , 1995, International journal of radiation oncology, biology, physics.

[34]  J. R. Stewart,et al.  Radiation injury to the heart. , 1995, International journal of radiation oncology, biology, physics.

[35]  H. Bartelink,et al.  EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. , 1995, International journal of radiation oncology, biology, physics.

[36]  J. Mulliken,et al.  Cutaneous vascular anomalies. , 1993, Seminars in vascular surgery.

[37]  L. Rutqvist,et al.  Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. , 1990, British Journal of Cancer.

[38]  B. Trock,et al.  Irradiation-related ischemic heart disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Trott.  Chronic damage after radiation therapy: challenge to radiation biology. , 1984, International journal of radiation oncology, biology, physics.